Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy associated with narcolepsy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor treatment for the chronic fatigue associated with the symptoms of Long-COVID; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist for improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. It has licensing agreements with NeuroLife-Sciences SAS for use of mazindol for the treatment of ADHD; and Eurofarma Laboratorios S.A. for commercialization and distribution of Nolazol in Latin America. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland. more
Time Frame | NLSP | Sector | S&P500 |
---|---|---|---|
1-Week Return | -25.83% | -1.8% | -0.77% |
1-Month Return | -49.37% | -3.48% | 0.71% |
3-Month Return | -61.08% | -7.2% | 8.81% |
6-Month Return | -61.67% | -1.54% | 12.32% |
1-Year Return | -88.45% | 8.39% | 30.57% |
3-Year Return | -96.1% | 6.07% | 29.21% |
5-Year Return | -98.26% | 44.07% | 91.95% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | - | - | 10.05K | 11.41K | 11.41K | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":88.1,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | - | - | (10.05K) | (11.41K) | (11.41K) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-1005000,"profit":false},{"date":"2022-12-31","value":-1140800,"profit":false},{"date":"2023-12-31","value":-1140800,"profit":false}] |
Gross Margin | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 4.20M | 2.30M | 11.85M | 15.47M | 11.81M | [{"date":"2019-12-31","value":27.13,"profit":true},{"date":"2020-12-31","value":14.86,"profit":true},{"date":"2021-12-31","value":76.6,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":76.32,"profit":true}] |
Operating Income | (4.20M) | (2.30M) | (11.86M) | (15.48M) | (11.81M) | [{"date":"2019-12-31","value":-419704000,"profit":false},{"date":"2020-12-31","value":-229937000,"profit":false},{"date":"2021-12-31","value":-1186062000,"profit":false},{"date":"2022-12-31","value":-1548236000,"profit":false},{"date":"2023-12-31","value":-1180706300,"profit":false}] |
Total Non-Operating Income/Expense | (2.07M) | (795.76K) | (153.59K) | (1.11M) | (510.12K) | [{"date":"2019-12-31","value":-206981600,"profit":false},{"date":"2020-12-31","value":-79576500,"profit":false},{"date":"2021-12-31","value":-15359100,"profit":false},{"date":"2022-12-31","value":-111418200,"profit":false},{"date":"2023-12-31","value":-51011900,"profit":false}] |
Pre-Tax Income | (5.45M) | (2.86M) | (11.95M) | (16.50M) | (12.17M) | [{"date":"2019-12-31","value":-544714500,"profit":false},{"date":"2020-12-31","value":-286143500,"profit":false},{"date":"2021-12-31","value":-1194607800,"profit":false},{"date":"2022-12-31","value":-1649568000,"profit":false},{"date":"2023-12-31","value":-1217202900,"profit":false}] |
Income Taxes | (4.20K) | (2.30K) | (226.51K) | 2.00 | 2.00 | [{"date":"2019-12-31","value":-209852,"profit":false},{"date":"2020-12-31","value":-114968.5,"profit":false},{"date":"2021-12-31","value":-11325400,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | (5.44M) | (2.86M) | (11.72M) | (16.50M) | (12.17M) | [{"date":"2019-12-31","value":-544294796,"profit":false},{"date":"2020-12-31","value":-285913563,"profit":false},{"date":"2021-12-31","value":-1171957000,"profit":false},{"date":"2022-12-31","value":-1649568200,"profit":false},{"date":"2023-12-31","value":-1217203100,"profit":false}] |
Income From Continuous Operations | (5.45M) | (2.86M) | (11.95M) | (16.50M) | (12.17M) | [{"date":"2019-12-31","value":-544714600,"profit":false},{"date":"2020-12-31","value":-286143500,"profit":false},{"date":"2021-12-31","value":-1194607800,"profit":false},{"date":"2022-12-31","value":-1649568000,"profit":false},{"date":"2023-12-31","value":-1217202800,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (5.45M) | (2.86M) | (11.95M) | (16.50M) | (12.17M) | [{"date":"2019-12-31","value":-544714500,"profit":false},{"date":"2020-12-31","value":-286143500,"profit":false},{"date":"2021-12-31","value":-1194607800,"profit":false},{"date":"2022-12-31","value":-1649568000,"profit":false},{"date":"2023-12-31","value":-1217202900,"profit":false}] |
EPS (Diluted) | (0.75) | (0.92) | (1.66) | - | - | [{"date":"2019-12-31","value":-74.61,"profit":false},{"date":"2020-12-31","value":-92.34,"profit":false},{"date":"2021-12-31","value":-166,"profit":false},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
NLSP | |
---|---|
Cash Ratio | 0.07 |
Current Ratio | 0.15 |
Quick Ratio | 0.12 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
NLSP | |
---|---|
ROA (LTM) | -227.76% |
ROE (LTM) | -862.92% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
NLSP | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 8.77 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -7.77 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
NLSP | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 4.84 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
NLS Pharmaceutics AG (NLSP) share price today is $2.01
Yes, Indians can buy shares of NLS Pharmaceutics AG (NLSP) on Vested. To buy NLS Pharmaceutics AG from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in NLSP stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of NLS Pharmaceutics AG (NLSP) via the Vested app. You can start investing in NLS Pharmaceutics AG (NLSP) with a minimum investment of $1.
You can invest in shares of NLS Pharmaceutics AG (NLSP) via Vested in three simple steps:
The 52-week high price of NLS Pharmaceutics AG (NLSP) is $24.34. The 52-week low price of NLS Pharmaceutics AG (NLSP) is $1.75.
The price-to-earnings (P/E) ratio of NLS Pharmaceutics AG (NLSP) is
The price-to-book (P/B) ratio of NLS Pharmaceutics AG (NLSP) is 4.84
The dividend yield of NLS Pharmaceutics AG (NLSP) is 0.00%
The market capitalization of NLS Pharmaceutics AG (NLSP) is $4.74M
The stock symbol (or ticker) of NLS Pharmaceutics AG is NLSP